Poplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedVV
Vida Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 1 First participation on record · 1 follow-on
- Funding in participating rounds
- $95M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$50MSeries A
Role not disclosed